Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Improving homology modeling from low-sequence identity templates in Rosetta: A case study in GPCRs.

Tytuł:
Improving homology modeling from low-sequence identity templates in Rosetta: A case study in GPCRs.
Autorzy:
Bender BJ; Department of Pharmacology, Department of Chemistry, and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, United States of America.
Marlow B; Department of Pharmacology, Department of Chemistry, and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, United States of America.
Meiler J; Department of Pharmacology, Department of Chemistry, and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, United States of America.; Institute for Drug Discovery, Leipzig University Medical School, Leipzig, SAC, Germany.
Źródło:
PLoS computational biology [PLoS Comput Biol] 2020 Oct 28; Vol. 16 (10), pp. e1007597. Date of Electronic Publication: 2020 Oct 28 (Print Publication: 2020).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science, [2005]-
MeSH Terms:
Models, Molecular*
Receptors, G-Protein-Coupled*/chemistry
Receptors, G-Protein-Coupled*/genetics
Sequence Homology, Amino Acid*
Computational Biology/*methods
Humans ; Sequence Alignment ; Sequence Analysis, Protein ; Software
References:
Curr Protoc Bioinformatics. 2016 Jun 20;54:5.6.1-5.6.37. (PMID: 27322406)
Trends Pharmacol Sci. 2011 Jan;32(1):35-42. (PMID: 21075459)
PLoS One. 2011;6(6):e20161. (PMID: 21731610)
J Biol Chem. 2015 Dec 4;290(49):29127-39. (PMID: 26420482)
PLoS One. 2016 May 16;11(5):e0154811. (PMID: 27182833)
Structure. 2011 Aug 10;19(8):1108-26. (PMID: 21827947)
Structure. 2015 Aug 4;23(8):1538-1549. (PMID: 26190572)
BMC Bioinformatics. 2004 Aug 19;5:113. (PMID: 15318951)
Biochim Biophys Acta. 2013 Nov;1828(11):2583-91. (PMID: 23871992)
Bioinformatics. 2008 Aug 1;24(15):1662-8. (PMID: 18474507)
Protein Sci. 2008 Jun;17(6):990-1002. (PMID: 18441233)
J Mol Biol. 1993 Dec 5;234(3):779-815. (PMID: 8254673)
Mol Pharmacol. 2018 Apr;93(4):251-258. (PMID: 29298813)
Methods Enzymol. 2004;383:66-93. (PMID: 15063647)
Nature. 2007 Nov 15;450(7168):383-7. (PMID: 17952055)
J Mol Biol. 2000 Sep 8;302(1):205-17. (PMID: 10964570)
Methods Enzymol. 2011;487:545-74. (PMID: 21187238)
Nucleic Acids Res. 2018 Jul 2;46(W1):W387-W395. (PMID: 29788177)
PLoS One. 2013 Jul 02;8(7):e67302. (PMID: 23844000)
PLoS One. 2013 Sep 06;8(9):e74092. (PMID: 24058518)
Proteins. 2016 Sep;84 Suppl 1:233-46. (PMID: 26343917)
Science. 2000 Aug 4;289(5480):739-45. (PMID: 10926528)
Science. 2007 Nov 23;318(5854):1258-65. (PMID: 17962520)
Nature. 2018 Mar 8;555(7695):269-273. (PMID: 29466326)
Science. 2010 Nov 19;330(6007):1091-5. (PMID: 21097933)
Nucleic Acids Res. 2018 Jan 4;46(D1):D440-D446. (PMID: 29155946)
Nucleic Acids Res. 2016 Jul 8;44(W1):W455-62. (PMID: 27166369)
Biochemistry. 2016 Aug 30;55(34):4748-63. (PMID: 27490953)
Nat Struct Mol Biol. 2018 Jun;25(6):488-495. (PMID: 29808000)
Proteins. 2006 Aug 15;64(3):559-74. (PMID: 16736488)
Mol Pharmacol. 2003 Jun;63(6):1256-72. (PMID: 12761335)
Nucleic Acids Res. 2017 Jul 3;45(W1):W408-W415. (PMID: 28582569)
Trends Pharmacol Sci. 2015 Jan;36(1):22-31. (PMID: 25541108)
Br J Pharmacol. 2012 Mar;165(6):1688-1703. (PMID: 21864311)
Nat Rev Drug Discov. 2017 Dec;16(12):829-842. (PMID: 29075003)
Methods Mol Biol. 2014;1079:105-16. (PMID: 24170397)
Nature. 2018 Apr;556(7702):520-524. (PMID: 29670288)
Nature. 1992 Jul 2;358(6381):86-9. (PMID: 1614539)
Nat Rev Drug Discov. 2008 Apr;7(4):339-57. (PMID: 18382464)
Structure. 2013 Oct 8;21(10):1735-42. (PMID: 24035711)
Acta Crystallogr D Biol Crystallogr. 2009 May;65(Pt 5):510-2. (PMID: 19390156)
Nucleic Acids Res. 2016 Jan 4;44(D1):D356-64. (PMID: 26582914)
Nat Struct Mol Biol. 2018 Jun;25(6):472-481. (PMID: 29867214)
Nat Protoc. 2017 Feb;12(2):401-416. (PMID: 28125104)
Grant Information:
R01 HL122010 United States HL NHLBI NIH HHS; P30 DK058404 United States DK NIDDK NIH HHS; R01 DA046138 United States DA NIDA NIH HHS; R01 GM129261 United States GM NIGMS NIH HHS; R01 GM080403 United States GM NIGMS NIH HHS
Substance Nomenclature:
0 (Receptors, G-Protein-Coupled)
Entry Date(s):
Date Created: 20201028 Date Completed: 20210127 Latest Revision: 20220329
Update Code:
20240104
PubMed Central ID:
PMC7652349
DOI:
10.1371/journal.pcbi.1007597
PMID:
33112852
Czasopismo naukowe
As sequencing methodologies continue to advance, the availability of protein sequences far outpaces the ability of structure determination. Homology modeling is used to bridge this gap but relies on high-identity templates for accurate model building. G-protein coupled receptors (GPCRs) represent a significant target class for pharmaceutical therapies in which homology modeling could fill the knowledge gap for structure-based drug design. To date, only about 17% of druggable GPCRs have had their structures characterized at atomic resolution. However, modeling of the remaining 83% is hindered by the low sequence identity between receptors. Here we test key inputs in the model building process using GPCRs as a focus to improve the pipeline in two critical ways: Firstly, we use a blended sequence- and structure-based alignment that accounts for structure conservation in loop regions. Secondly, by merging multiple template structures into one comparative model, the best possible template for every region of a target can be used expanding the conformational space sampled in a meaningful way. This optimization allows for accurate modeling of receptors using templates as low as 20% sequence identity, which accounts for nearly the entire druggable space of GPCRs. A model database of all non-odorant GPCRs is made available at www.rosettagpcr.org. Additionally, all protocols are made available with insights into modifications that may improve accuracy at new targets.
Competing Interests: The authors have declared that no competing interests exist.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies